Skip to main content
Premium Trial:

Request an Annual Quote

GSK to Use Gentronix Genotoxicity Assays

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Gentronix today said that it has signed a three-year deal with GlaxoSmithKline, under which it will provide the drug maker with its GeneScreen HC and BlueScreen HC genotoxicity assays.

The Manchester, UK-based assay developer said that the agreement extends a pact with GSK for the GreenScreen HC to include the BlueScreen HC in 384-well format, which is its latest human cell reporter-based assay for compound profiling.

John Nicholson, chairman and CEO of Gentronix, said that the alliance "provides additional validation for our technology and provides an opportunity for our customers to take advantage of the benefits of early liability screening for more cost effective drug discovery and development."

Financial and other terms of the agreement were not disclosed.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.